Shahidi Shahrzad, Hoseinbalam Marziyeh, Iraj Bijan, Akbari Mojtaba
Isfahan Kidney Disease Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Int J Nephrol. 2015;2015:259592. doi: 10.1155/2015/259592. Epub 2015 Mar 22.
Background. Pentoxifylline is a nonspecific phosphodiesterase inhibitor with anti-inflammatory properties. Human studies have proved its antiproteinuric effect in patients with glomerular diseases, but this study was designed to assess the effects of add-on pentoxifylline to available treatment on reduction of microalbuminuria in diabetic patients without glomerular diseases. Methods. In a double-blind placebo-controlled, randomized study we evaluated the influence of pentoxifylline on microalbuminuria in type 2 diabetic patients. 40 diabetic patients with estimated glomerular filtration rate (eGFR) of more than 60 mL/min/1.73 m(2) in eight weeks and microalbuminuria were randomized to two groups which will receive pentoxifylline 1200 mg/day or placebo added to regular medications for 6 months. albuminuria; eGFR was evaluated at three- and six-month follow-up period. Results. Baseline characteristics were similar between the two groups. At six months, the mean estimated GFR and albuminuria were not different between two groups at 3- and 6-month follow-up. Trend of albumin to creatinine ratio, systolic and diastolic blood pressure, and eGFR in both groups were decreased, but no significant differences were noted between two groups (P value > 0.05). Conclusion. Pentoxifylline has not a significant additive antimicroalbuminuric effect compared with placebo in patients with type 2 diabetes with early stage of kidney disease; however, further clinical investigations are necessary to be done.
背景。己酮可可碱是一种具有抗炎特性的非特异性磷酸二酯酶抑制剂。人体研究已证实其对肾小球疾病患者有抗蛋白尿作用，但本研究旨在评估在现有治疗基础上加用己酮可可碱对无肾小球疾病的糖尿病患者微量白蛋白尿减少的影响。方法。在一项双盲安慰剂对照的随机研究中，我们评估了己酮可可碱对2型糖尿病患者微量白蛋白尿的影响。40例估计肾小球滤过率（eGFR）大于60 mL/min/1.73 m²且有微量白蛋白尿的糖尿病患者被随机分为两组，分别接受每日1200 mg己酮可可碱或在常规药物基础上加用安慰剂，为期6个月。在3个月和6个月的随访期评估蛋白尿和eGFR。结果。两组的基线特征相似。在6个月时，两组在3个月和6个月随访时的平均估计GFR和蛋白尿无差异。两组的白蛋白与肌酐比值、收缩压和舒张压以及eGFR均呈下降趋势，但两组间无显著差异（P值>0.05）。结论。在早期肾病的2型糖尿病患者中，与安慰剂相比，己酮可可碱没有显著的附加抗微量白蛋白尿作用；然而，仍有必要进行进一步的临床研究。
